BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 3017717)

  • 1. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
    Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
    Eur J Biochem; 1986 Aug; 159(1):45-9. PubMed ID: 3017717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Properties of vasoactive-intestinal-peptide receptors and beta-adrenoceptors in the murine radiation leukemia-virus-induced lymphoma cell line BL/VL3.
    Abello J; Damien C; De Neef P; Tastenoy M; Hooghe R; Robberecht P; Christophe J
    Eur J Biochem; 1989 Aug; 183(2):263-7. PubMed ID: 2547606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
    Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
    Eur J Biochem; 1987 Jun; 165(2):243-9. PubMed ID: 3036504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas.
    Robberecht P; Waelbroeck M; Coy D; De Neef P; Camus JC; Christophe J
    Peptides; 1986; 7 Suppl 1():53-9. PubMed ID: 3018703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of HIS1 modifications on the ability of vasoactive intestinal peptide to stimulate adenylate cyclase from rat and human tissues.
    Robberecht P; Waelbroeck M; Camus JC; De Neef P; Coy D; Christophe J
    Peptides; 1984; 5(5):877-81. PubMed ID: 6504721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
    Waelbroeck M; Robberecht P; Coy DH; Camus JC; De Neef P; Christophe J
    Endocrinology; 1985 Jun; 116(6):2643-9. PubMed ID: 2859987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of VIP receptors in human lung membranes.
    Robberecht P; Waelbroeck M; de Neef P; Camus JC; Coy DH; Christophe J
    Peptides; 1988; 9(2):339-45. PubMed ID: 2836826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of the novel helodermin/VIP receptor present in human SUP-T1 lymphoma cell membranes.
    Robberecht P; De Neef P; Gourlet P; Cauvin A; Coy DH; Christophe J
    Regul Pept; 1989; 26(2):117-26. PubMed ID: 2552509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of vasoactive intestinal peptide and its stimulation of adenylate cyclase through two classes of receptors in rat liver membranes. Effects of 12 secretin analogues and 2 secretin fragments.
    Waelbroeck M; Robberecht P; De Neef P; Chatelain P; Christophe J
    Biochim Biophys Acta; 1981 Nov; 678(1):83-90. PubMed ID: 6272875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effector mechanisms of peptides of the VIP family.
    Christophe J; Svoboda M; Lambert M; Waelbroeck M; Winand J; Dehaye JP; Vandermeers-Piret MC; Vandermeers A; Robberecht P
    Peptides; 1986; 7 Suppl 1():101-7. PubMed ID: 3018687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive intestinal peptide receptors in pancreas and liver. Structure-function relationship.
    Christophe J; Svoboda M; Waelbroeck M; Winand J; Robberecht P
    Ann N Y Acad Sci; 1988; 527():238-56. PubMed ID: 2839079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M; Couvineau A; Rouyer-Fessard C
    Mol Pharmacol; 1986 Jan; 29(1):23-7. PubMed ID: 3003561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
    Rodríguez-Pena MS; Guijarro LG; Prieto JC
    Eur J Pharmacol; 1991 Nov; 208(3):207-12. PubMed ID: 1663044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new type of functional VIP receptor has an affinity for helodermin in human SUP-T1 lymphoblasts.
    Robberecht P; Waelbroeck M; De Neef P; Tastenoy M; Gourlet P; Cogniaux J; Christophe J
    FEBS Lett; 1988 Feb; 228(2):351-5. PubMed ID: 2830146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
    Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
    Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selectivity for binding of peptide analogs to vascular receptors for vasoactive intestinal peptide.
    Rorstad OP; Wanke I; Coy DH; Fournier A; Huang M
    Mol Pharmacol; 1990 Jun; 37(6):971-7. PubMed ID: 2163020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of vasoactive intestinal peptide receptors coupled to adenylate cyclase in rat lung membranes.
    Robberecht P; Chatelain P; De Neef P; Camus JC; Waelbroeck M; Christophe J
    Biochim Biophys Acta; 1981 Nov; 678(1):76-82. PubMed ID: 6118184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural requirements for the binding of the pituitary adenylate-cyclase-activating peptide to receptors and adenylate-cyclase activation in pancreatic and neuronal membranes.
    Gourlet P; Woussen-Colle MC; Robberecht P; de Neef P; Cauvin A; Vandermeers-Piret MC; Vandermeers A; Christophe J
    Eur J Biochem; 1991 Jan; 195(2):535-41. PubMed ID: 1997328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activation of adenylate cyclase by pituitary adenylate cyclase activating polypeptide (PACAP) via helodermin-preferring VIP receptors in human SUP-T1 lymphoblastic membranes.
    Gourlet P; De Neef P; Woussen-Colle MC; Vandermeers A; Vandermeers-Piret MC; Robberecht P; Christophe J
    Biochim Biophys Acta; 1991 Jul; 1066(2):245-51. PubMed ID: 1649637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural requirements for VIP interaction with specific receptors in human and rat intestinal membranes: effect of nine partial sequences.
    Couvineau A; Rouyer-Fessard C; Fournier A; St Pierre S; Pipkorn R; Laburthe M
    Biochem Biophys Res Commun; 1984 Jun; 121(2):493-8. PubMed ID: 6329205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.